NeurologyLive® Friday 5 — March 28, 2025

Author(s):

Key Takeaways

Epilepsy awareness initiatives focus on dispelling myths and addressing treatment gaps, with new innovations highlighted by Dr. Luis Tornes.
Dr. Matthew Alexander discusses targeted therapies for muscular dystrophies, emphasizing key signaling pathways in treatment.
Cognitive decline differentiation in MS and AD is explored by Dr. Sarah Levy, with orientation as a key distinguishing factor.
Neural regeneration therapies in ALS and other neurodegenerative diseases are discussed by Dr. Kuldip Dave, highlighting potential functional restoration.
Persistent challenges in NMOSD diagnosis and treatment, including misdiagnosis and disparities in care, are addressed by Sumaira Ahmed.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 28, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Epilepsy Unveiled: Addressing Myths, Treatment Gaps, and New Innovations

Luis Tornes, MD, a neurologist and director of Baptist Health’s Epilepsy Program, provided clinical insights on raising awareness for Purple Day, a global initiative dedicated for patients and families with epilepsy.

2: Exploring New Avenues for Treating Muscular Dystrophies With Targeted Therapies: Matthew Alexander, PhD

The associate professor of pediatric neurology and genetics at the University of Alabama Birmingham provided clinical insights on the key signaling pathways currently being targeted in the treatment of muscular dystrophies. [WATCH TIME: 4 minutes]

3: Differentiating Cognitive Decline in Multiple Sclerosis and Alzheimer Disease: Sarah Levy, PhD

The assistant professor in the department of neurology at Mount Sinai discussed distinguishing cognitive impairment in MS from AD emphasizing orientation as a key differentiator. [WATCH TIME: 5 minutes]

4: NeuroVoices: Kuldip Dave, PhD, on Exploring Neural Regeneration in ALS and Beyond

The senior vice president of research at The ALS Association discussed insights into neural regeneration therapies and their potential to restore function in neurodegenerative diseases.

5: Addressing Persistent Challenges in NMOSD Diagnosis and Treatment: Sumaira Ahmed

Despite advancements in NMOSD treatments, the founder and executive director of the Sumaira Foundation discussed how misdiagnosis, delayed diagnosis, and disparities in care remain significant challenges. [WATCH TIME: 4 minutes]